NYSE:LLY<\/a>) and Boehringer Ingelheim have developed Abasaglar in Europe, which is a biosimilar version of Lantus.<\/p>\n\n\n\nDIABETES EXECUTIVE SHAKE UP<\/h3>\n\n\n\n According to the company, due to the management shuffle, Pascale Witz, Executive-in-charge for diabetes and cardiovascular division will leave in a week. This departure represents major changes in Sanofi\u2019s executive committee under the five-year plan, “2020 strategic roadmap” revealed in November 2015.<\/p>\n\n\n\n
NOVO NORDISK ROLE<\/h3>\n\n\n\n The technical team of Novo Nordisk has to work very closely with the FDA to convince them regarding the combination program of Tresiba (insulin degludec) and Victoza (liraglutide) in a once-a-day formulation, IDegLira.<\/p>\n\n\n\n
According to the drugmaker, the combination has shown comprehensive results in the management and treatment of diabetes either used alone or in combined form. On the other hand, the internal assessment of the combo showed a biased design in the favor of combo formulation.<\/p>\n\n\n\n
IDegLira is thought to be the blockbuster drug of Novo and is able to capture a major chunk from the multibillion-dollar therapeutic market. The formulation of the combo is delayed due to the Tresiba\u2019s two-year delayed approval.<\/p>\n\n\n\n
Analysts are optimistic regarding the sale of IDegLira, which has already been approved in Europe by the name of Xultophy with an estimated revenue of $1 billion.<\/p>\n\n\n\n
Novo Nordisk is emphasizing the point that the combo is a better formulation consisting of molecules that help in controlling blood sugar along with reducing the complications in insulin use.<\/p>\n\n\n\n
COMPANIES IN MARKET<\/h3>\n\n\n\n The companies working in the therapeutic market of diabetes mainly depend on upon the GLP-1.<\/p>\n\n\n\n
Novo Nordisk has a strong and competitive drug portfolio comprising Victoza (liraglutide) and Levemir. The new addition of Tresiba has already hit the European market and showing its efficacy and safety profile by gaining momentum. In 2015, the drugmaker has also launched Ryzodeg in Mexico, which is a combo product of Tresiba and NovoLog.<\/p>\n\n\n\n
Novo\u2019s drug pipeline is robust. The drugmaker is working on the investigational molecule, OG217SC, which is an oral formulation of Novo\u2019s injectable semaglutide.<\/p>\n\n\n\n
By virtue of the drug pipeline and its profile, Novo can easily double its revenue generation in a decade. According to Novo Ceo Kare Schultz, by 2020, approximately 40 million diabetic patients will use Novo diabetic care products.<\/p>\n\n\n\n
Merck has clinched approximately $7.4 billion in 2014, which is 0.75% down as compared to 2013. The drugmaker is mainly dependent upon its Januvia and Janumet combo pill. The company is facing fierce competition from the generics and is showing a slow decline in the sales. The company is working diligently on its DPP-4 drugs as Januvia has passed a key cardiac safety test in a clinical study.<\/p>\n\n\n\n
According to Bernstein & Co. analyst Tim Anderson, the positive result can boost the sale of the Januvia and Janumet to 10% by 2020.<\/p>\n\n\n\n
In addition to the aforementioned companies, Pfizer also snagged $7.3 billion and Eli Lilly racked $4.5 from the global diabetic therapeutic market. Pfizer is working on multiple options such as to acquire novel molecules or acquiring small companies having investigational molecules in the field of diabetes.<\/p>\n\n\n\n
On the other hand, Eli Lilly is dependent on its insulin formulation, Humalog. For the backup plan, the drugmaker will use Trulicity, Glyxambi, which Eli Lilly markets with Boehringer, and Synjardy, marketed in combination formulation will affect the market sales in the coming years.<\/p>\n","protected":false},"excerpt":{"rendered":"
It is too early to predict FDA\u2019s verdict regarding the approval of Sanofi combo drug for the treatment of diabetes Sanofi SA (NYSE:SNY) came into the spotlight after Food and Drug Administration (FDA) initiated a debate in association with its Diabetes Mellitus Type II combo drug LixiLan pointing out number of questions regarding the safety … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"footnotes":""},"categories":[6],"tags":[],"yoast_head":"\nSanofi SA (ADR) and Diabetes: Things Are Not Working Out - Business Finance<\/title>\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\t \n\t \n\t \n